H.F. 712 Summary

• Amends Minnesota Statutes to define "biological product" per federal law (42 U.S.C. § 262) and establishes new definition of "interchangeable biological product" based on FDA approval standards or therapeutic equivalence determinations.

• Prohibits pharmacists from substituting biological products unless the FDA has determined the substitute to be interchangeable with the prescribed product, requiring pharmacist professional judgment and purchaser notification.

• Requires pharmacists to communicate the name and manufacturer of any dispensed biological product to the prescriber within five business days through electronic medical records, e-prescribing technology, pharmacy benefit management systems, or other secure means.

• Modifies prescription substitution rules to clarify "dispense as written" requirements for paper, electronic, and oral prescriptions, and prohibits prescribers from maintaining "dispense as written" as a default on all electronic prescriptions.

• Preserves existing pharmacy substitution provisions for generic drugs regarding pricing, disclosure, and extended supply dispensing (up to 90-day supplies after initial 30-day fill).